|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Cymabay Therapeutics, Inc. (CBAY) |
|
|
$32.48 0.00 (0.00%) as of 4:30 Thu 3/21
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
114,780,000 |
Market
Cap: |
3.73(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$7.47 - $32.48 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing and providing access to therapies for patients with liver and other chronic diseases. Co.'s pipeline includes the following clinical stage product candidates: seladelpar, a selective agonist for the peroxisome proliferator-activated receptor delta, which is a nuclear receptor that regulates genes involved in bile acid/sterol, lipid, and glucose metabolism, and regulation of certain inflammatory cells; and MBX-2982, which targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
51,301 |
Total Buy Value |
$0 |
$0 |
$0 |
$100,037 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
6,000 |
242,302 |
552,511 |
672,611 |
Total Sell Value |
$191,849 |
$4,799,466 |
$8,944,114 |
$10,085,429 |
Total People Sold |
1 |
5 |
6 |
7 |
Total Sell Transactions |
1 |
15 |
33 |
36 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Dickinson Klara |
Chief Regulatory Officer |
|
2024-03-22 |
4 |
D |
$0.00 |
$0 |
D/D |
(21,000) |
0 |
|
- |
|
Mcwherter Charles |
President of R&D |
|
2024-03-22 |
4 |
D |
$0.00 |
$0 |
D/D |
(46,938) |
0 |
|
- |
|
Shah Sujal |
Chief Executive Officer |
|
2024-03-22 |
4 |
D |
$0.00 |
$0 |
D/D |
(406,670) |
0 |
|
- |
|
Quinlan Paul T |
General Counsel |
|
2024-03-22 |
4 |
D |
$0.00 |
$0 |
D/D |
(70,262) |
0 |
|
- |
|
Emster Kurt Von |
|
|
2024-03-22 |
4 |
D |
$0.00 |
$0 |
D/D |
(90,000) |
0 |
|
- |
|
Shantharam Harish |
Chief Financial Officer |
|
2024-03-22 |
4 |
D |
$0.00 |
$0 |
D/D |
(20,125) |
0 |
|
- |
|
Wills Robert James |
|
|
2024-03-22 |
4 |
D |
$0.00 |
$0 |
D/D |
(30,000) |
0 |
|
- |
|
Shah Sujal |
Chief Executive Officer |
|
2024-03-13 |
4 |
OE |
$1.06 |
$655,959 |
D/D |
139,119 |
406,670 |
|
- |
|
Quinlan Paul T |
General Counsel |
|
2024-03-13 |
4 |
OE |
$7.89 |
$329,991 |
D/D |
41,824 |
70,262 |
|
- |
|
Dorling Janet |
Director |
|
2024-02-12 |
4 |
AS |
$31.97 |
$191,849 |
D/D |
(6,000) |
0 |
|
1% |
|
Dorling Janet |
Director |
|
2024-02-12 |
4 |
OE |
$4.63 |
$27,780 |
D/D |
6,000 |
6,000 |
|
- |
|
Dickinson Klara |
Chief Regulatory Officer |
|
2024-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
21,000 |
21,000 |
|
- |
|
Quinlan Paul T |
General Counsel |
|
2024-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
28,438 |
28,438 |
|
- |
|
Shah Sujal |
Chief Executive Officer |
|
2024-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
96,250 |
267,551 |
|
- |
|
Mcwherter Charles |
President of R&D |
|
2024-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
31,938 |
46,938 |
|
- |
|
Shantharam Harish |
Chief Financial Officer |
|
2024-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
20,125 |
20,125 |
|
- |
|
Mcwherter Charles |
President of R&D |
|
2024-01-19 |
4 |
AS |
$23.66 |
$435,645 |
D/D |
(18,403) |
15,000 |
|
33% |
|
Mcwherter Charles |
President of R&D |
|
2024-01-19 |
4 |
OE |
$1.06 |
$130,522 |
D/D |
18,403 |
18,125 |
|
- |
|
Quinlan Paul T |
General Counsel |
|
2024-01-16 |
4 |
AS |
$23.58 |
$117,898 |
D/D |
(5,000) |
0 |
|
34% |
|
Quinlan Paul T |
General Counsel |
|
2024-01-16 |
4 |
OE |
$2.94 |
$14,700 |
D/D |
5,000 |
5,000 |
|
- |
|
Menold Daniel |
Vice President, Finance |
|
2024-01-16 |
4 |
AS |
$23.58 |
$235,806 |
D/D |
(10,000) |
0 |
|
34% |
|
Menold Daniel |
Vice President, Finance |
|
2024-01-16 |
4 |
OE |
$4.05 |
$40,500 |
D/D |
10,000 |
10,000 |
|
- |
|
Dorling Janet |
Director |
|
2024-01-10 |
4 |
AS |
$23.86 |
$143,144 |
D/D |
(6,000) |
0 |
|
39% |
|
Dorling Janet |
Director |
|
2024-01-10 |
4 |
OE |
$4.63 |
$27,780 |
D/D |
6,000 |
6,000 |
|
- |
|
Mcwherter Charles |
President of R&D |
|
2023-12-18 |
4 |
AS |
$21.48 |
$243,441 |
D/D |
(11,332) |
15,000 |
|
44% |
|
156 Records found
|
|
Page 1 of 7 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|